CLINICAL_TRIALS
research
· 2008-07-24
Clinical Trial Update: BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma [Phase 2]
Summary
Phase 2 clinical trial update on BAY 59-8862 for refractory Non-Hodgkin lymphoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Theradex | Conditions: Lymphoma | Phase 2 | Status: UNKNOWN